For example, Denman et al. (2012) developed an ex vivo NK cell expansion with large quantities for patient infusion in several clinical trials for myeloid malignancies and posterior fossa tumors, these expanded NK cells secrete large amounts of IFNγ compared to primary NK cells. The gene discussed is IFNG; the disease is myeloid neoplasm.